share_log

Ladenburg Thalmann Maintains Buy on Capricor Therapeutics, Raises Price Target to $25

Ladenburg Thalmann Maintains Buy on Capricor Therapeutics, Raises Price Target to $25

拉登堡塔尔曼维持对Capricor Therapeutics的买入,将目标股价上调至25美元
Benzinga ·  05/14 14:23

Ladenburg Thalmann analyst Aydin Huseynov maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price target from $24 to $25.

拉登堡塔尔曼分析师艾登·侯赛诺夫维持Capricor Therapeutics(纳斯达克股票代码:CAPR)的买入并将目标股价从24美元上调至25美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发